Acute exudative paraneoplastic polymorphous vitelliform maculopathy during vemurafenib and pembrolizumab treatment for metastatic melanoma

Conclusion: This case report suggests that acute exudative polymorphous vitelliform maculopathy may be directly associated with the use of BRAF inhibitors as treatment for metastatic cutaneous melanoma, or indirectly by triggering autoimmune–paraneoplastic processes. Future identification of similar associations is required to unequivocally link vemurafenib and/or pembrolizumab to acute exudative polymorphous vitelliform maculopathy in metastatic melanoma.
Source: Retinal Cases and Brief Reports - Category: Opthalmology Tags: Case Report Source Type: research